AbbVie Inc. (ABBV) Stock

AbbVie Inc. (ABBV) is a Healthcare stock trading at $254.50 (as of 2026-07-17), with a market capitalization of $449.65B and a trailing P/E of 123.7. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

I can’t produce a description that follows your rules because the company’s SEC 10-K “Business” (Item 1) text wasn’t provided. Paste the AbbVie 10-K Item 1 section, and I’ll summarize it in 1–2 sentences (~45 words) based only on those facts.

Understand AbbVie Inc.: how it makes money

AbbVie develops and sells prescription pharmaceuticals, including HUMIRA (autoimmune and intestinal Behcet's injections), SKYRIZI (plaque psoriasis), RINVOQ (rheumatoid arthritis), IMBRUVICA and VENCLEXTA (selected blood cancers), and MAVYRET (chronic conditions), and it makes money primarily from product net revenues across these therapies.

AbbVie's profit model is structurally driven by the scale of its Immunology portfolio, because the company’s largest revenue pool comes from Immunology products like HUMIRA and SKYRIZI, while other portfolios (Neuroscience, HemOnc, Aesthetics) are smaller contributors.

Revenue by segment (latest quarter)
Immunology$8.6B
Neuroscience$3.0B
HemOnc$1.9B
Aesthetics$1.2B

Business quality (Mixed): The company’s pipeline of commercial products spans multiple therapy areas, but the provided figures show Immunology as the dominant revenue driver, so quarterly performance tends to hinge on that portfolio.

Valuation: At 116× earnings, ABBV trades 587% above the Pharmaceutical Products average (17×). Note: one-time items can distort reported P/E.

Bull case

  • Diversified product set across major therapy areas: AbbVie sells multiple branded therapies spanning Immunology, Neuroscience, oncology, and Aesthetics.
  • Immunology is the largest portfolio by provided revenue figures: Immunology portfolio net revenues are provided as 8.6B, versus smaller portfolio figures for Neuroscience (2.96B), HemOnc (1.9B), and Aesthetics (1.2B).

Bear case

  • Greater sensitivity to Immunology portfolio outcomes: Because Immunology is the largest provided revenue pool, changes in that portfolio can have an outsized impact on overall performance.
  • Limited offset from smaller portfolios if Immunology underperforms: The provided portfolio revenue figures show other portfolios (Neuroscience, HemOnc, Aesthetics) are smaller than Immunology, so they may not fully offset weaker Immunology results.
Valuation — source: SEC EDGAR (first-party)
Price$254.50
Market Cap$449.65B
P/E Ratio123.7
EV / EBITDA27.3
Price / Sales7.16
FCF Yield4.4%
DCF Value (model)$91.63
DCF Upside vs Price-64.0%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$61.16B
Net Margin6.9%
Revenue Growth (YoY)12.4%
EPS Growth (YoY)-45.8%
FCF Growth (YoY)154.6%
Financial Health — source: SEC EDGAR
Altman Z-Score2.51 (grey)
Piotroski F-Score6/9 (moderate)
Valuation vs Sector & Industry
Stock P/E123.7
Sector P/E (Healthcare)21.4
Industry P/E (Pharmaceutical Products)17.0
vs Sector477.1%
vs Industry629.0%
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Insider Sells (12mo)2
Top Institutional HolderVANGUARD GROUP INC ($41.31B)
Institutional Holders Tracked10
Congressional Trades (recent)10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEORobert A. Michael
Employees55,000
CountryUS
IPO Date2013-03-15

Related Companies (Business model: Big Pharma / Branded Drugs; 8 closest by market cap; US-domiciled)

  • Eli Lilly and Company (LLY)
  • Johnson & Johnson (JNJ)
  • Merck & Co., Inc. (MRK)
  • Abbott Laboratories (ABT)
  • Pfizer Inc. (PFE)
  • Bristol-Myers Squibb Company (BMY)
  • Vertex Pharmaceuticals Incorporated (VRTX)
  • Regeneron Pharmaceuticals, Inc. (REGN)
ABBV earnings history · ABBV institutional & insider holders · ABBV KPIs & operating metrics · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-07-17.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.